Actuate Therapeutics Announces Poster Presentations at the 2023 ASCO Annual Meeting

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023, in Chicago, Illinois.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Tuesday, May 30, 2023

Information

Tags:

PDAC, Abstract, Survival, Clinical trial, Cancer, Disposable and discretionary income, Actuate, ASCO, Patient, Plasma, Colorectal cancer, Annual general meeting, Therapy, Society, American Society of Clinical Oncology, Pharmaceutical industry

Geotags:

FT. WORTH, TEXAS, US, CHICAGO, ILLINOIS

⚠ generated by AI ↴

Organisation:

ACTUATE THERAPEUTICS, ACTUATE THERAPEUTICS, INC.

Summary

Key Points:

CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023, in Chicago, Illinois.
The abstracts are currently available on the ASCO meeting website .
The posters will be available online at https://actuatetherapeutics.com/news-media/ following the presentations.
Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.

CHICAGO and FORT WORTH, Texas, May 30, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023, in Chicago, Illinois.

The abstracts are currently available on the ASCO meeting website. The posters will be available online at https://actuatetherapeutics.com/news-media/ following the presentations.

Poster Presentation Details:

In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.
Presentation Type: Poster Presentation
Date/Time: Saturday, June 3, 2023, 8:00 AM - 11:00 AM
Presenter: Joseph McDermott, Lantern Pharma Inc., Dallas TX
Abstract Number: 3079

Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).
Presentation Type: Online Publication
Presenter: Dr. Devalingam Mahalingam, Northwestern University, Chicago, IL
Abstract Number: e16289

Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.
Presentation Type: Online Publication
Presenter: Taylor Weiskittel, Mayo Clinic, Rochester, MN
Abstract Number: e14555

GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.
Presentation Type: Online Publication
Presenter: Dr. Wafik S. El-Deiry, Brown University, Providence, RI
Abstract Number: e15138

About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.

CONTACT:
Public Relations Dept.,
Actuate Therapeutics, Inc.
+1 (847) 986-4190
[email protected]